Skip to main content
EnglishEN
European Commission logo print header

Isotopic Labeling of Biotherapeutics

Project description

DEENESFRITPL

A new labelling strategy for biological drugs

Recent years have witnessed the introduction into the clinic of biological drugs such as peptides, proteins and oligonucleotides due to their specificity and low toxicity compared to chemical drugs. Analysis of the pharmacokinetics of biological drugs requires the incorporation of radioisotopes that enable tracing of the drug’s journey in the body. However, radiolabelling of reduced-size biological drugs poses a significant challenge. Funded by the Marie Skłodowska-Curie Actions programme, the ISOBIOTICS project aims to develop a novel radiolabelling strategy suitable for small molecules such as peptides. This will further advance research and development of biotherapeutics with improved targeting efficiency and lower immunogenicity.

Objective

Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities entering clinical trials reaches the market (1 on 16 for chemical drugs). Consequently, 15 on 24 top blockbuster drugs were biotherapeutics in 2020 (world-market share of about 40% of $175 billion of revenue per year). In order to reduce the immunogenicity of biodrugs, to overcome their fragility and to increase their capacity to reach quickly and massively their target, reduced-size biologics are extensively developed. However, radiolabeling of large molecules by grafting bifunctional chelating agents which do not alter significantly their biological activity is thus no longer possible with smaller biodrugs. It is therefore of paramount importance to devise new radiolabeling approaches carried out on tiny quantities in aqueous media and very soft conditions. It is also crucial to train a new generation of radiochemists in order to implement these methods and to meet the needs of the European industry. ISOBIOTICS ambitions: 1) to develop new chemically-benign strategies for the last-stage radiolabeling of large peptides, small/medium-size proteins, oligonucleotides and analogs with deuterium, tritium and carbon-14 (preclinical and phase 0 clinical evaluation), and fluorine-18 (phase I-III clinical trials); 2) to educate a new generation of young talented PhD students specialized in the radiolabeling of biologics through a combination of interdisciplinary lab research, transdisciplinary and intersectorial secondments, technical taught courses, scientific lectures and complementary skills workshops; 3) to ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS outputs in order to maximize the project’s impact and radiance; 4) to secure the students employment and the sustainability of training structures.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

HORIZON-MSCA-2021-DN-01

See other projects for this call

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Net EU contribution
€ 848 080,80
Address
Rue leblanc 25
75015 Paris
France

See on map
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Other funding
€ 0,00

Participants (5)

Partners (10)

Share this page

Download

EC signature date 14 July 2022
Last update: 4 September 2022

My Booklet

Permalink: https://cordis.europa.eu/project/id/101072780

European Union, 2023